07:55 AM EDT, 08/12/2024 (MT Newswires) -- scPharmaceuticals (SCPH) said Monday the US Food and Drug Administration has approved the company's supplemental new drug application to expand the Furoscix indication for heart failure patients.

Furoscix was previously only indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association Class I and Class III chronic heart failure, while the new indication now includes patients with Class IV chronic heart failure.

Shares of the company retreated more than 8% in recent pre-bell activity Monday.

Price: 3.9800, Change: -0.35, Percent Change: -8.08